Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges

MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modali...

Full description

Bibliographic Details
Main Authors: Kinan Alhallak, Jennifer Sun, Amanda Jeske, Chaelee Park, Jessica Yavner, Hannah Bash, Berit Lubben, Ola Adebayo, Ayah Khaskiah, Abdel Kareem Azab
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
bispecific T cell engagers
chimeric antigen receptor-T cells
multiple myeloma
Online Access:https://www.mdpi.com/2072-6694/13/12/2853
id doaj-e5d4e588e8054614aa888fdb2002ffc6
record_format Article
spelling doaj-e5d4e588e8054614aa888fdb2002ffc62021-06-30T23:34:42ZengMDPI AGCancers2072-66942021-06-01132853285310.3390/cancers13122853Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and ChallengesKinan Alhallak0Jennifer Sun1Amanda Jeske2Chaelee Park3Jessica Yavner4Hannah Bash5Berit Lubben6Ola Adebayo7Ayah Khaskiah8Abdel Kareem Azab9Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USADepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USADepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USADepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USADepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USADepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USADepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USADepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USAFaculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit 627, West Bank, PalestineDepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USAMM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.https://www.mdpi.com/2072-6694/13/12/2853bispecific T cell engagerschimeric antigen receptor-T cellsmultiple myeloma
collection DOAJ
language English
format Article
sources DOAJ
author Kinan Alhallak
Jennifer Sun
Amanda Jeske
Chaelee Park
Jessica Yavner
Hannah Bash
Berit Lubben
Ola Adebayo
Ayah Khaskiah
Abdel Kareem Azab
spellingShingle Kinan Alhallak
Jennifer Sun
Amanda Jeske
Chaelee Park
Jessica Yavner
Hannah Bash
Berit Lubben
Ola Adebayo
Ayah Khaskiah
Abdel Kareem Azab
Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
Cancers
bispecific T cell engagers
chimeric antigen receptor-T cells
multiple myeloma
author_facet Kinan Alhallak
Jennifer Sun
Amanda Jeske
Chaelee Park
Jessica Yavner
Hannah Bash
Berit Lubben
Ola Adebayo
Ayah Khaskiah
Abdel Kareem Azab
author_sort Kinan Alhallak
title Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
title_short Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
title_full Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
title_fullStr Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
title_full_unstemmed Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
title_sort bispecific t cell engagers for the treatment of multiple myeloma: achievements and challenges
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-06-01
description MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.
topic bispecific T cell engagers
chimeric antigen receptor-T cells
multiple myeloma
url https://www.mdpi.com/2072-6694/13/12/2853
work_keys_str_mv AT kinanalhallak bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
AT jennifersun bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
AT amandajeske bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
AT chaeleepark bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
AT jessicayavner bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
AT hannahbash bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
AT beritlubben bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
AT olaadebayo bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
AT ayahkhaskiah bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
AT abdelkareemazab bispecifictcellengagersforthetreatmentofmultiplemyelomaachievementsandchallenges
_version_ 1721351053875609600

Similar Items